Presentation

Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, CAN10 entering clinical studies early 2022, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).

Cantargia AB was formed in 2009-2010 and is focused on research towards the inflammatory receptor IL1RAP, involved in the development of several life-threating diseases